News | January 20, 2009

Radiation Lowers Relapse Risk in Noninvasive Breast Cancer

January 21, 2009 - Adding radiation therapy to lumpectomy in the treatment of ductal carcinoma in situ (DCIS) substantially decreases the risk of recurrence of either DCIS or invasive breast cancer in the affected breast, according to a study from Westmead Hospital in Australia and the University of Sydney.

Annabel Goodwin, M.D., the study’s co-author, and colleagues from the Westmead Hospital in Australia and the University of Sydney looked at recent studies that evaluated the addition of radiation therapy after lumpectomy in the treatment of DCIS. They also found that there appear to be no long-term side effects from the radiation, such as damage to the heart or lungs.

"We wanted to assess whether breast conserving surgery followed by radiotherapy is better than breast conserving surgery alone," Goodwin said. "We also wanted to investigate if there was any short- or long-term toxicity from the use of radiotherapy to determine the balance between benefit and harm."

The review appears in the latest issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

The researchers identified four high-quality studies that compared breast-conserving surgery with or without radiation therapy in patients with DCIS. The review included data from 3,925 women.

DCIS is different from invasive breast cancer in that abnormal, precancerous cells form within the milk duct of the breast but do not spread to other parts of the breast. If treated, it is usually curable. However, if left untreated, it substantially increases a woman's chance of developing invasive breast cancer.

Women usually cannot feel a lump in the breast with DCIS usually cannot be felt as a lump in the breast, but a mammogram can often detect it. Breast-conserving surgery where only the affected part of the breast is removed followed by radiation, is successful for most.

The reviewers found that the addition of radiation therapy after breast conserving surgery decreases the risk of recurrence of either DCIS or invasive breast cancer in the treated breast by 51 percent.

"This means that for every nine women having breast-conserving surgery [for DCIS], if they all had radiotherapy, one woman would be spared from having a local recurrence of her breast cancer because of the radiotherapy," Goodwin said. She added that the results of two included studies suggested that women over 50 had a greater benefit from the addition of radiotherapy than younger women did.

The researchers found no evidence of increased long-term toxicity from the radiation treatment. "Newer techniques of radiation therapy reduce the dose of radiation to the surrounding normal tissues such as the lungs and heart," Goodwin said. "This is likely to reduce the potential long term side effects, but longer term follow up of patients in these studies is needed to confirm this."

Surgical oncologist and breast cancer expert Monica Morrow, M.D., from the Memorial Sloan-Kettering Cancer Center, said that the review confirms what most physicians currently recommend for their patients with DCIS who opt for breast-conserving treatment. "The best way to minimize the chance of recurrence is with radiation," she said.

Survival rates the percentage of women who are alive after a certain period after diagnosis are excellent for women with DCIS, no matter whether they choose mastectomy or breast-conserving therapy. In patients who have breast-conserving therapy with or without radiation therapy, survival rates range from 90 percent to 99 percent at 10 years.

Doctors overwhelmingly favor breast-conserving therapy for DCIS, Morrow said. However, many women in the U.S. choose more aggressive treatment with mastectomy.

"Studies show that the bigger the patient's role in decision-making, the greater the likelihood the patient will end up with mastectomy," she said. "This is because most patients don't distinguish between DCIS and invasive breast cancer, because a lot of the stuff they find on the Internet is written about invasive cancer."

While it is true that the risk of having a recurrence of breast cancer after a mastectomy is lower than after breast conserving therapy in DCIS, Morrow said there is not much difference in survival rates. "What I tend to emphasize to my patients with DCIS is that no matter which treatment they choose, their risk over the next 15 years of dying of something else is greater than their risk of dying of breast cancer. In the end the difference of survival, if there is any, is on the order of a percent or two."

Goodwin A, et al. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database of Systematic Reviews 2009, Issue 1.

Source: Health Behavior News Service

For more information: www.hbns.org and www.cochrane.org

Related Content

Sponsored Content | Videos | Proton Therapy | August 21, 2017
Mark Pankuch, Ph.D., director of medical physics at the Northwestern Medicine Chicago Proton Center, discusses the cl
Summit Cancer Center-Boise Treats First Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | August 21, 2017
Accuray Inc. and the Summit Cancer Center-Boise announced that the center is now treating patients with the Radixact...
MedStar Georgetown Proton Center Selects RayStation for Treatment Planning
News | Treatment Planning | August 17, 2017
August 17, 2017 — The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on
DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
First Radixact Results Presented at AAPM 2017
News | Radiation Therapy | August 10, 2017
Accuray Inc. announced that the first studies validating the benefits of the Radixact System were presented at the 59th...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Aktina’s interchangeable cones are lightweight and extremely accurate
News | Radiation Therapy | August 02, 2017
Aktina Medical announced a collaboration with Philips Medical Systems and Elekta Instruments for SRS interlocking at...
News | Image Guided Radiation Therapy (IGRT) | July 31, 2017
Elekta’s magnetic resonance radiation therapy (MR/RT) system will be the subject of 21 abstracts at the 59th American...
Accuray Receives 510(k) Clearance for iDMS Data Management System
Technology | Oncology Information Management Systems (OIMS) | July 31, 2017
July 31, 2017 — Accuray Inc. announced it has received 510(k) clearance from the U.S.
Overlay Init